Oramed Pharmaceuticals
ORMP
21 hedge funds and large institutions have $1.96M invested in Oramed Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 3 closing their positions.
6% more capital invested
Capital invested by funds: $1.85M → $1.96M (+$113K)
0% more funds holding
Funds holding: 21 → 21 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0.1% less ownership
Funds ownership: 1.92% → 1.83% (-0.1%)
26% less call options, than puts
Call options by funds: $17K | Put options by funds: $23K
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$203K |
| 2 |
Wells Fargo
San Francisco,
California
|
+$18.9K |
| 3 |
AG
Advisor Group
Phoenix,
Arizona
|
+$7.25K |
| 4 |
Citigroup
New York
|
+$6.2K |
| 5 |
LC
Landaas & Company
Milwaukee,
Wisconsin
|
+$1.67K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$121K |
| 2 |
EMG
ETF Managers Group
Summit,
New Jersey
|
-$86K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$53.1K |
| 4 |
Morgan Stanley
New York
|
-$32.3K |
| 5 |
FANJ
Financial Architects (New Jersey)
Marlton,
New Jersey
|
-$18K |
ORMP Hedge Fund Activity: Q2 2018 in Review
21 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q2 2018, worth a combined $1.96M — up 6.1% from $1.85M a quarter earlier.
Fund positioning in ORMP was balanced in Q2 2018: 3 funds opened new positions, 3 closed out, 2 added to existing stakes and 4 trimmed.
The largest buyer was BlackRock, opening a new position worth an estimated $203K. The largest seller was Renaissance Technologies, cutting an estimated $121K.
- 21 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q2 2018, unchanged from Q1 2018.
- Funds reported $1.96M of Oramed Pharmaceuticals stock for Q2 2018, up 6.1% quarter-over-quarter.
- 3 funds opened new Oramed Pharmaceuticals positions in Q2 2018 and 3 closed out, a net change of 0 holders.
- The largest Oramed Pharmaceuticals buyer in Q2 2018 was BlackRock, an estimated $203K added.
- The largest Oramed Pharmaceuticals seller in Q2 2018 was Renaissance Technologies, an estimated $121K sold.
Based on aggregated 13F filings for Q2 2018.